FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200210268> ?p ?o ?g. }

• W4200210268 endingPage "e003580" @default.
• W4200210268 startingPage "e003580" @default.
• W4200210268 abstract "Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced gastric cancer.Phase 2, open-label, randomized multicenter study evaluating the efficacy, safety, and pharmacodynamics of ADX+NIVO versus NIVO in patients with pretreated metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events (AEs). We explored the correlation of efficacy outcomes with biomarkers.144 patients were randomized; 141 were treated: 81% white, 69% male, median age was 61 years in the ADX+NIVO group and 62 years in the NIVO-alone group. The ORR was 10% (95% CI 4 to 19) in the ADX+NIVO group and 7% (95% CI 2 to 16) in the NIVO-alone group (OR: 1.5 (95% CI 0.4 to 6.1; p=0.8)). There was no response or survival benefit associated with adding ADX. AE rates were comparable in both treatment groups; the most common AEs were fatigue, decreased appetite, nausea, and vomiting. Programmed cell death ligand 1, interferon-γ (IFN), and intratumoral CD8+ cell density were not associated with treatment response or survival. The gene signature most correlated with shorter survival was the epithelial-to-mesenchymal gene signature; high transforming growth factor (TGF)-β fibrosis score was negatively associated with OS (p=0.036). Gene expression analysis of baseline tumors comparing long-(1+ years) and short-term (<1 year) survivors showed that GRB7 was associated with survival beyond 1 year. Human epidermal growth factor receptor 2 (HER2)-positive disease was associated with significantly longer survival (p=0.0077). Median tumor mutation burden (TMB) was 2.01; patients with TMB ≥median had longer survival (p=0.0025) and improved PFS (p=0.016). Based on a model accounting for TMB, TGF-β fibrosis, and HER2, TMB was the main driver of survival in this patient population.Combination of ADX+NIVO had a favorable safety profile but did not improve efficacy compared with NIVO alone in patients with pretreated metastatic gastric or GEJ adenocarcinoma. HER2 positivity, higher TMB or GRB7, and lower TGF-β were associated with improved outcomes.NCT02864381 or GS-US-296--2013." @default.
• W4200210268 created "2021-12-31" @default.
• W4200210268 creator A5002759193 @default.
• W4200210268 creator A5014572822 @default.
• W4200210268 creator A5016437917 @default.
• W4200210268 creator A5019473289 @default.
• W4200210268 creator A5022845423 @default.
• W4200210268 creator A5038494072 @default.
• W4200210268 creator A5038948612 @default.
• W4200210268 creator A5042529049 @default.
• W4200210268 creator A5044392059 @default.
• W4200210268 creator A5048303857 @default.
• W4200210268 creator A5056345420 @default.
• W4200210268 creator A5066306425 @default.
• W4200210268 creator A5078170323 @default.
• W4200210268 creator A5080894198 @default.
• W4200210268 creator A5082208955 @default.
• W4200210268 creator A5085786563 @default.
• W4200210268 creator A5089202777 @default.
• W4200210268 creator A5090645179 @default.
• W4200210268 date "2021-12-01" @default.
• W4200210268 modified "2023-10-15" @default.
• W4200210268 title "Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival" @default.
• W4200210268 cites W1479960756 @default.
• W4200210268 cites W1581404300 @default.
• W4200210268 cites W16797474 @default.
• W4200210268 cites W1919257374 @default.
• W4200210268 cites W1983606789 @default.
• W4200210268 cites W1987313355 @default.
• W4200210268 cites W1988556605 @default.
• W4200210268 cites W2002246796 @default.
• W4200210268 cites W2003432147 @default.
• W4200210268 cites W2005334224 @default.
• W4200210268 cites W2011716233 @default.
• W4200210268 cites W2012293350 @default.
• W4200210268 cites W2016859011 @default.
• W4200210268 cites W2020947105 @default.
• W4200210268 cites W2036791863 @default.
• W4200210268 cites W2039719564 @default.
• W4200210268 cites W2056539843 @default.
• W4200210268 cites W2060638936 @default.
• W4200210268 cites W2062268212 @default.
• W4200210268 cites W2085558818 @default.
• W4200210268 cites W2089666322 @default.
• W4200210268 cites W2094929011 @default.
• W4200210268 cites W2103441770 @default.
• W4200210268 cites W2104759721 @default.
• W4200210268 cites W2107018762 @default.
• W4200210268 cites W2111237964 @default.
• W4200210268 cites W2111281047 @default.
• W4200210268 cites W2114104545 @default.
• W4200210268 cites W2114734455 @default.
• W4200210268 cites W2123114542 @default.
• W4200210268 cites W2123879591 @default.
• W4200210268 cites W2128244648 @default.
• W4200210268 cites W2130410032 @default.
• W4200210268 cites W2130430382 @default.
• W4200210268 cites W2132871418 @default.
• W4200210268 cites W2134785517 @default.
• W4200210268 cites W2136280424 @default.
• W4200210268 cites W2137526110 @default.
• W4200210268 cites W2150495188 @default.
• W4200210268 cites W2156077962 @default.
• W4200210268 cites W2158710755 @default.
• W4200210268 cites W2167198989 @default.
• W4200210268 cites W2169456326 @default.
• W4200210268 cites W2214074259 @default.
• W4200210268 cites W2293531514 @default.
• W4200210268 cites W2347070489 @default.
• W4200210268 cites W2408932313 @default.
• W4200210268 cites W2497174208 @default.
• W4200210268 cites W2590748692 @default.
• W4200210268 cites W2591053562 @default.
• W4200210268 cites W2592811885 @default.
• W4200210268 cites W2593030814 @default.
• W4200210268 cites W2593659832 @default.
• W4200210268 cites W2606495925 @default.
• W4200210268 cites W2627067328 @default.
• W4200210268 cites W2655262992 @default.
• W4200210268 cites W2751474182 @default.
• W4200210268 cites W2763064222 @default.
• W4200210268 cites W2783337717 @default.
• W4200210268 cites W2785803176 @default.
• W4200210268 cites W2793364080 @default.
• W4200210268 cites W2801869430 @default.
• W4200210268 cites W2806614796 @default.
• W4200210268 cites W2808750176 @default.
• W4200210268 cites W2883552436 @default.
• W4200210268 cites W2889459498 @default.
• W4200210268 cites W2903322254 @default.
• W4200210268 cites W2909679049 @default.
• W4200210268 cites W2945045362 @default.
• W4200210268 cites W2948359678 @default.
• W4200210268 cites W2949273159 @default.
• W4200210268 cites W2952238748 @default.
• W4200210268 cites W3024911178 @default.
• W4200210268 cites W3042132061 @default.
• W4200210268 cites W3083986479 @default.

• next